Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb

Resmed (RMD) reported robust fiscal fourth-quarter and full-year 2025 results, surpassing analyst estimates with Q4 adjusted EPS up 22.6% to $2.55 and revenues increasing 10.2% to $1.35 billion. This strong performance was fueled by resilient global demand for its sleep and breathing health devices, growth in residential care software, and significant gross and operating margin expansion driven by efficiency improvements. The company's enhanced financial position, marked by increased cash reserves and reduced debt, led to a 2.6% rise in RMD shares in after-market trading, reflecting investor confidence in its operational strength and market leadership.

Analysis

Resmed Inc. (RMD) delivered a robust fiscal fourth-quarter 2025 performance, significantly exceeding consensus estimates on both revenue and earnings. The company reported a 10.2% year-over-year revenue increase to $1.35 billion, surpassing forecasts by 1.87%, driven by sustained global demand in its core Sleep and Breathing Health segment (+10.2%). Adjusted EPS grew an impressive 22.6% to $2.55, beating estimates by 3.66%. A key highlight was the substantial margin expansion, with the adjusted gross margin widening by 227 basis points to 61.4% and the adjusted operating margin expanding by 260 basis points to 35.3%. This improvement was attributed to procurement, manufacturing, and logistics efficiencies, signaling successful execution of its margin initiatives. The company's financial health has strengthened considerably, with cash reserves growing to $1.21 billion and total debt declining to $668.3 million. This robust financial position enabled the return of capital to shareholders through $78 million in dividends and $100 million in share repurchases, reflecting management's confidence and contributing to a 2.6% after-market rise in the share price.

Key Decisions for Investors

• Investors should view the strong top-line beat, double-digit earnings growth, and significant margin expansion as confirmation of Resmed's robust market position and operational efficiency.
• Monitor the company's ability to sustain its gross margin, which reached 61.4%, and track the integration and revenue synergy contribution from the recent VirtuOx acquisition as key indicators of future performance.
• Given the strong balance sheet improvement and active capital return program, consider the current valuation in light of the 2.6% after-hours share price appreciation and the neutral 'Hold' rating from Zacks.